Replimune Group, Inc..
REPL.US | Research and experimental development on natural sciences and engineering
Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies. These therapies are designed to selectively replicate within tumors and elicit a systemic anti-tumor immune response, leading to the destruction of the tumor and long-lasting immunity. The company's lea...Show More
Better Health for All
40
Replimune demonstrates a commitment to better health for all through its development of oncolytic immunotherapies, particularly RP1, for treating solid tumors. Clinical trial data from the IGNYTE study shows a 33.6% overall response rate in anti-PD1 failed melanoma patients, with responses lasting over 6 months and a median duration exceeding 35 months
1
. The company is also initiating the IGNYTE-3 clinical trial, a Phase 3 study, to further evaluate the efficacy and safety of RP1 in combination with nivolumab for advanced melanoma
2
. Treatment-related adverse events were primarily Grade 1-2, indicating a manageable safety profile
3
,
4
. The company's focus on innovative cancer treatments and promising clinical trial results support a positive score. However, the company is still in the clinical stage, and there is no data on price accessibility or vulnerable population reach, which limits a higher score.
5
,
6
,
7
,
8
,
9
,
10
Fair Money & Economic Opportunity
0
Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies, not a financial institution.
1
The 'Fair Money & Economic Opportunity' value assesses companies involved in lending, insuring, moving, or storing money. The provided articles do not contain any evidence related to Replimune's involvement in financial services or offering financial products to consumers.
2
Therefore, none of the KPIs under this value are applicable or can be scored based on the available information.
Fair Pay & Worker Respect
0
As of March 31, 2025, the company reported 479 employees, none of whom are represented by a labor organization or under any collective bargaining arrangements.
1
The company also states that no specific regulatory actions, violations, or fines related to labor practices are mentioned in the provided text.
2
While the company offers a variety of competitive benefits, including health insurance plans, for its employees, the percentage of the workforce covered by these plans is not specified.
3
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any information regarding Replimune Group, Inc.'s supply chain, sourcing practices, or adherence to fair trade principles.
1
Therefore, no assessment can be made against the 'Fair Trade & Ethical Sourcing' value based on the evidence provided.
Honest & Fair Business
0
No specific, quantitative, or detailed qualitative evidence was found in the provided articles to assess Replimune Group, Inc. against any of the 'Honest & Fair Business' KPIs. explicitly states that it "does not contain any quantitative data relevant to the requested metrics" and mentions "No regulatory actions, violations, fines, certifications, awards, comparisons to industry benchmarks, or contradictions are mentioned."
1
While it refers to corporate governance documents and a code of conduct, these general mentions lack the specific details required by the rubric for scoring KPIs such as whistleblower policy strength, board independence, or anti-corruption policy enforcement.
2
was unavailable and provided no data.
3
Kind to Animals
0
The provided articles indicate that Replimune Group, Inc. conducts preclinical laboratory tests and animal studies in compliance with good laboratory practice (GLP) regulations.
1
However, no specific, scorable evidence was found for any of the KPIs related to the 'Kind to Animals' value. There is no information regarding the percentage of products certified cruelty-free, the extent of non-animal testing methods employed by the company, or the percentage of animal-related operations holding humane certifications.
2
Data on wildlife conservation impact, the replacement of animal-derived ingredients, or the auditing of animal-related suppliers is not available.
3
The articles do not provide details on cage-free sourcing, the volume of animals used in testing, the percentage of R&D budget invested in animal-free technologies, participation in multi-stakeholder initiatives for animal-free standards, or engagement in animal welfare policy improvement.
4
No War, No Weapons
0
Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its activities primarily revolving around research, development, and clinical testing.
1
The provided articles, which include press releases on public offerings,
2
clinical trial results,
3
and internal grant policies,
4
contain no information or data points indicating any involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any other defense-related activities. Therefore, all KPIs related to 'No War, No Weapons' are scored as N/A, reflecting that these activities are not part of the company's core business or operations.
Planet-Friendly Business
0
The provided articles do not contain any specific, quantifiable data points or concrete facts related to Replimune Group, Inc.'s environmental performance. While some articles mention the company's ESG score or industry ranking, they explicitly state that no specific ESG metrics, such as greenhouse gas emissions, renewable energy usage, water consumption, waste diversion rates, or any climate-related targets or initiatives, are detailed or quantifiable.
1
Therefore, there is no evidence to score any of the Planet-Friendly Business KPIs.
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles regarding Replimune Group, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities. The articles focus on the company's oncolytic immunotherapy platform, clinical trials, expanded access programs, and individual patient access policies, without addressing community engagement, cultural impact, or related social responsibility metrics.
1
Safe & Smart Tech
10
Replimune's privacy policy outlines user rights, including the ability to access, correct, delete, restrict processing, object to processing, withdraw consent, and request data portability.
1
The company states it does not collect or retain sensitive personal data related to health, ethnic origin, religious beliefs, or political conviction unless explicitly submitted.
2
Replimune aims to comply with laws, regulations, and guidance, including local data privacy law, and uses EU Model Clauses for data transfer from the EU/EEA to the US or UK.
3
Zero Waste & Sustainable Products
0
Replimune Group, Inc. diverts 93% of its generated laboratory waste through recycling or neutralization.
1
The company achieved a 48% hazardous waste reduction rate and generates 0.7 metric tons of chemical waste annually.
2